NovaBay Pharmaceuticals (NBY) Receivables (2016 - 2025)
Historic Receivables for NovaBay Pharmaceuticals (NBY) over the last 15 years, with Q3 2025 value amounting to $368000.0.
- NovaBay Pharmaceuticals' Receivables fell 4772.73% to $368000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $368000.0, marking a year-over-year decrease of 4772.73%. This contributed to the annual value of $680000.0 for FY2023, which is 6553.47% down from last year.
- According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Receivables is $368000.0, which was down 4772.73% from $704000.0 recorded in Q3 2024.
- NovaBay Pharmaceuticals' 5-year Receivables high stood at $2.6 million for Q2 2023, and its period low was $300000.0 during Q1 2022.
- Moreover, its 5-year median value for Receivables was $1.0 million (2021), whereas its average is $1.2 million.
- As far as peak fluctuations go, NovaBay Pharmaceuticals' Receivables soared by 51166.67% in 2023, and later tumbled by 7914.6% in 2024.
- Over the past 5 years, NovaBay Pharmaceuticals' Receivables (Quarter) stood at $1.7 million in 2021, then rose by 16.95% to $2.0 million in 2022, then plummeted by 65.53% to $680000.0 in 2023, then rose by 3.53% to $704000.0 in 2024, then tumbled by 47.73% to $368000.0 in 2025.
- Its Receivables was $368000.0 in Q3 2025, compared to $704000.0 in Q3 2024 and $547000.0 in Q2 2024.